"Kill-switch" enabled, immune-silent, non-cytopathic, and persistent paramyxovirus vector for respiratory gene therapy.

用于呼吸系统基因治疗的具有“杀伤开关”功能、免疫沉默、非细胞病变且持久的副粘病毒载体。

• 批准号: 339029
• 负责人: Thibault Patricia A
• 金额: $ 10.93万
• 依托单位: Mount Sinai Hospital (New York)
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-11-01 至 2018-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=339029&lang=en
• 关键词: Gene Therapy; Immune-Silent; Interferon Antagonism; Paramyxoviruses; Persistent Infection; Protease Inhibitors; Respiratory Therapy; Sendai Virus; Viral Pathogenesis; Viral Vector

There is a need for effective lung-tropic viral gene delivery vectors for treatment of genetic lung disorders like Cystic Fibrosis, or for prophylactic delivery of broadly neutralizing antibodies against human respiratory pathogens (e.g. influenza or RSV)

需要有效的嗜肺病毒基因传递载体，用于治疗遗传性肺部疾病，如囊性纤维化，或用于预防性传递针对人类呼吸道病原体（如流感或RSV）的广泛中和抗体。